Procept Biorobotics (PRCT)
$68.26
Live
Performance
- $67.48$69.65$68.26
1.14%
Downside
Day's Volatility :3.12%
Upside
2.0%
- $24.83$85.81$68.26
63.62%
Downside
52 Weeks Volatility :71.06%
Upside
20.45%
Returns
| Period | Procept Biorobotics | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | -0.22% | 3.6% | 0.0% |
6 Months | 34.69% | 10.2% | 0.0% |
1 Year | 154.71% | 19.6% | 0.0% |
3 Years | 61.17% | 16.8% | -23.0% |
Highlights
Market Capitalization | 3.6B |
Book Value | $4.85 |
Earnings Per Share (EPS) | -2.06 |
Wall Street Target Price | 89.83 |
Profit Margin | -58.73% |
Operating Margin TTM | -50.28% |
Return On Assets TTM | -21.19% |
Return On Equity TTM | -50.88% |
Revenue TTM | 176.6M |
Revenue Per Share TTM | 3.5 |
Quarterly Revenue Growth YOY | 61.199999999999996% |
Gross Profit TTM | 37.1M |
EBITDA | -104.8M |
Diluted Eps TTM | -2.06 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.88 |
EPS Estimate Next Year | -1.46 |
EPS Estimate Current Quarter | -0.52 |
EPS Estimate Next Quarter | -0.49 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 31.6%
Company Financials
| FY19 | Y/Y Change | |
|---|---|---|
Revenue | 6.2M | - |
Net Income | -42.7M | - |
Net Profit Margin | -691.41% | - |
| FY20 | Y/Y Change | |
|---|---|---|
Revenue | 7.7M | ↑ 25.09% |
Net Income | -58.3M | ↑ 36.58% |
Net Profit Margin | -754.89% | ↓ 63.48% |
| FY21 | Y/Y Change | |
|---|---|---|
Revenue | 34.5M | ↑ 346.72% |
Net Income | -62.4M | ↑ 7.09% |
Net Profit Margin | -180.96% | ↑ 573.93% |
| FY22 | Y/Y Change | |
|---|---|---|
Revenue | 75.0M | ↑ 117.6% |
Net Income | -93.6M | ↑ 50.01% |
Net Profit Margin | -124.76% | ↑ 56.2% |
| FY23 | Y/Y Change | |
|---|---|---|
Revenue | 136.2M | ↑ 81.55% |
Net Income | -105.9M | ↑ 13.16% |
Net Profit Margin | -77.76% | ↑ 47.0% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 24.4M | ↑ 2.64% |
Net Income | -27.7M | ↓ 11.5% |
Net Profit Margin | -113.53% | ↑ 18.13% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 33.1M | ↑ 35.65% |
Net Income | -25.3M | ↓ 8.73% |
Net Profit Margin | -76.38% | ↑ 37.15% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 35.1M | ↑ 6.04% |
Net Income | -24.6M | ↓ 2.62% |
Net Profit Margin | -70.14% | ↑ 6.24% |
| Q4 FY23 | Q/Q Change | |
|---|---|---|
Revenue | 43.6M | ↑ 24.16% |
Net Income | -27.5M | ↑ 11.7% |
Net Profit Margin | -63.11% | ↑ 7.03% |
| Q1 FY24 | Q/Q Change | |
|---|---|---|
Revenue | 44.5M | ↑ 2.2% |
Net Income | -26.0M | ↓ 5.62% |
Net Profit Margin | -58.28% | ↑ 4.83% |
| Q2 FY24 | Q/Q Change | |
|---|---|---|
Revenue | 53.4M | ↑ 19.79% |
Net Income | -25.6M | ↓ 1.28% |
Net Profit Margin | -48.03% | ↑ 10.25% |
| FY19 | Y/Y Change | |
|---|---|---|
Total Assets | 62.0M | - |
Total Liabilities | 205.8M | - |
| FY20 | Y/Y Change | |
|---|---|---|
Total Assets | 126.0M | ↑ 103.2% |
Total Liabilities | 308.9M | ↑ 50.06% |
| FY21 | Y/Y Change | |
|---|---|---|
Total Assets | 337.0M | ↑ 167.54% |
Total Liabilities | 69.9M | ↓ 77.36% |
| FY22 | Y/Y Change | |
|---|---|---|
Total Assets | 309.3M | ↓ 8.22% |
Total Liabilities | 112.3M | ↑ 60.52% |
| FY23 | Y/Y Change | |
|---|---|---|
Total Assets | 404.7M | ↑ 30.84% |
Total Liabilities | 124.0M | ↑ 10.43% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 284.5M | ↓ 8.04% |
Total Liabilities | 111.3M | ↓ 0.82% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 272.4M | ↓ 4.22% |
Total Liabilities | 116.5M | ↑ 4.68% |
| Q3 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 421.1M | ↑ 54.57% |
Total Liabilities | 121.8M | ↑ 4.48% |
| Q4 FY23 | Q/Q Change | |
|---|---|---|
Total Assets | 404.7M | ↓ 3.9% |
Total Liabilities | 124.0M | ↑ 1.8% |
| Q1 FY24 | Q/Q Change | |
|---|---|---|
Total Assets | 382.9M | ↓ 5.39% |
Total Liabilities | 118.9M | ↓ 4.12% |
| Q2 FY24 | Q/Q Change | |
|---|---|---|
Total Assets | 374.4M | ↓ 2.23% |
Total Liabilities | 122.6M | ↑ 3.13% |
| FY19 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -43.8M | - |
Investing Cash Flow | 43.2M | - |
Financing Cash Flow | 26.5M | - |
| FY20 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -48.3M | ↑ 10.33% |
Investing Cash Flow | -233.0K | ↓ 100.54% |
Financing Cash Flow | 106.8M | ↑ 302.5% |
| FY21 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -57.3M | ↑ 18.6% |
Investing Cash Flow | -592.0K | ↑ 154.08% |
Financing Cash Flow | 262.1M | ↑ 145.49% |
| FY22 | Y/Y Change | |
|---|---|---|
Operating Cash Flow | -80.4M | ↑ 40.2% |
Investing Cash Flow | -2.7M | ↑ 348.14% |
Financing Cash Flow | 3.6M | ↓ 98.62% |
| Q1 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | -35.9M | ↑ 42.72% |
Investing Cash Flow | -5.3M | ↑ 516.51% |
Financing Cash Flow | 380.0K | ↓ 128.83% |
| Q2 FY23 | Q/Q Change | |
|---|---|---|
Operating Cash Flow | -28.3M | ↓ 21.12% |
Investing Cash Flow | -5.4M | ↑ 0.62% |
Financing Cash Flow | 2.4M | ↑ 539.47% |
Technicals Summary
Sell
Neutral
Buy
Procept Biorobotics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Procept Biorobotics | -14.06% | 34.69% | 154.71% | 61.17% | 64.4% |
 Stryker Corporation | 0.83% | 12.78% | 40.21% | 33.69% | 71.83% |
 Boston Scientific Corp. | 4.85% | 29.48% | 75.68% | 96.28% | 127.87% |
 Edwards Lifesciences Corp. | 4.32% | -19.19% | 1.77% | -39.29% | -7.22% |
 Abbott Laboratories | 3.99% | 11.51% | 24.65% | -4.53% | 46.22% |
 Medtronic Plc | 2.65% | 14.48% | 27.42% | -24.18% | -13.49% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Procept Biorobotics | 53.06 | NA | NA | -1.88 | -0.51 | -0.21 | NA | 4.85 |
Stryker Corporation | 40.15 | 40.15 | 2.64 | 12.01 | 0.19 | 0.07 | 0.01 | 51.86 |
Boston Scientific Corp. | 70.26 | 70.26 | 2.14 | 2.41 | 0.09 | 0.05 | NA | 13.85 |
Edwards Lifesciences Corp. | 27.67 | 27.67 | 3.65 | 2.6 | 0.22 | 0.12 | NA | 12.35 |
Abbott Laboratories | 35.83 | 35.83 | 4.31 | 4.67 | 0.14 | 0.06 | 0.02 | 22.26 |
Medtronic Plc | 30.23 | 30.23 | 1.67 | 5.2 | 0.08 | 0.04 | 0.03 | 37.39 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Procept Biorobotics | Buy | $3.6B | 64.4% | 53.06 | -58.73% |
Stryker Corporation | Buy | $137.1B | 71.83% | 40.15 | 16.12% |
Boston Scientific Corp. | Buy | $127.3B | 127.87% | 70.26 | 12.0% |
Edwards Lifesciences Corp. | Buy | $42.3B | -7.22% | 27.67 | 23.74% |
Abbott Laboratories | Buy | $205.1B | 46.22% | 35.83 | 13.65% |
Medtronic Plc | Buy | $115.2B | -13.49% | 30.23 | 12.06% |
Insights on Procept Biorobotics
Increasing Revenue
Revenue is up for the last 17 quarters, 1.19M → 53.35M (in $), with an average increase of 19.6% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -27.50M → -25.62M (in $), with an average increase of 3.6% per quarter
Vs BSX
In the last 3 years, Boston Scientific Corp. has given 96.3% return, outperforming this stock by 35.1%
Institutional Holdings
FMR Inc
14.04%Vanguard Group Inc
9.07%BlackRock Inc
6.71%AllianceBernstein L.P.
3.48%T. Rowe Price Investment Management,Inc.
3.36%Champlain Investment Partners, LLC
2.63%
Company Information
based in silicon valley, procept biorobotics is a privately held surgical robotics company enabling better patient care by developing transformative solutions in urology. with an initial focus on benign prostatic hyperplasia (bph), the company’s first product, the aquabeam system delivering aquablation therapy, is the world’s first commercially available minimally invasive surgical robot providing autonomous tissue removal to safely and effectively treat bph. aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy or surgeon experience.
Organization | Procept Biorobotics |
Employees | 626 |
CEO | Dr. Reza Zadno Ph.D. |
Industry | Healthcare |
